Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 3/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.43 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.41 |
| ▸ | CDC42BPB | Q9Y5S2 | 6/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL99682 | 1.00 | PRKCI (0.49) | PRKCINUDT1AURKBAURKAINCENP | |
| SCHEMBL16692485 | 0.85 | PRKCI (0.48) | PRKCINUDT1AURKBAURKAINCENP | |
| SCHEMBL29540441 | 0.85 | AURKB (0.56) | PRKCINUDT1AURKBAURKAINCENP | |
| SCHEMBL98273 | 0.85 | AURKB (0.56) | PRKCINUDT1AURKBAURKAINCENP | |
| SCHEMBL99293 | 0.82 | PRKCI (0.45) | PRKCINUDT1AURKBAURKAINCENP | |
| SCHEMBL29541139 | 0.82 | PRKCI (0.45) | PRKCINUDT1AURKBAURKAINCENP | |
| SCHEMBL100026 | 0.81 | PRKCI (0.44) | PRKCINUDT1AURKBAURKAINCENP | |
| SCHEMBL29540476 | 0.81 | PRKCI (0.44) | PRKCINUDT1AURKBAURKAINCENP | |
| SCHEMBL99826 | 0.81 | PRKCI (0.44) | PRKCIAURKBAURKAINCENPTPX2 | |
| SCHEMBL29540628 | 0.81 | PRKCI (0.44) | PRKCIAURKBAURKAINCENPTPX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | PRKCI 304/4885NUDT1 1879/4885AURKB 198/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | PRKCI 304/4885NUDT1 1879/4885AURKB 198/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | PRKCI 304/4885NUDT1 1879/4885AURKB 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.